Table 2.
Detailed hereditary cancer risk assessment results by clinic
| Overall |
WCC |
MCC |
FTR |
p value | |||||
|---|---|---|---|---|---|---|---|---|---|
| N | %a | N | %a | N | %a | N | %a | ||
| Hereditary cancer risk assessment | 0.03 | ||||||||
| High/known mutation | 332 | 66.4 | 120 | 65.2 | 194 | 68.3 | 18 | 56.3 | |
| Moderate | 102 | 20.4 | 41 | 22.3 | 57 | 20.1 | 4 | 12.5 | |
| Average | 66 | 13.2 | 23 | 12.5 | 33 | 11.6 | 10 | 31.3 | |
| High risk | |||||||||
| Breast-ovarian (non-Ashkenazi Jewish) | 124 | 24.8 | 67 | 36.4 | 44 | 15.5 | 13 | 40.6 | <0.0001 |
| Breast-ovarian (Ashkenazi Jewish) | 6 | 1.2 | 1 | 0.5 | 5 | 1.8 | 0 | 0.0 | 0.61 |
| Breast (Ashkenazi Jewish) | 3 | 0.6 | 2 | 1.1 | 1 | 0.4 | 0 | 0.0 | 0.64 |
| Ovarian (Ashkenazi Jewish) | 4 | 0.8 | 3 | 1.6 | 1 | 0.4 | 0 | 0.0 | 0.47 |
| Colon/HNPCC | 168 | 33.6 | 32 | 17.4 | 134 | 47.2 | 2 | 6.3 | <0.0001 |
| Prostate | 6 | 1.2 | 2 | 1.1 | 2 | 0.7 | 2 | 6.3 | 0.04 |
| Lung | 1 | 0.2 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0.43 |
| Melanoma | 6 | 1.2 | 4 | 2.2 | 2 | 0.7 | 0 | 0.0 | 0.38 |
| Stomach | 3 | 0.6 | 1 | 0.5 | 1 | 0.4 | 1 | 3.1 | 0.23 |
| Li-Fraumeni | 5 | 1.0 | 1 | 0.5 | 2 | 0.7 | 2 | 6.3 | 0.05 |
| MEN1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | – |
| MEN2/thyroid | 3 | 0.6 | 2 | 1.1 | 1 | 0.4 | 0 | 0.0 | 0.64 |
| Cluster (all)b | 19 | 3.8 | 7 | 3.8 | 9 | 3.2 | 3 | 9.4 | 0.20 |
| Known mutation/clinical diagnosisc | 55 | 11.0 | 23 | 12.5 | 32 | 11.3 | 0 | 0.0 | 0.08 |
| Moderate risk | |||||||||
| Ovarian (non-Ashkenazi Jewish) | 59 | 11.8 | 52 | 28.3 | 7 | 2.5 | 0 | 0.0 | <0.0001 |
| Breast (non-Ashkenazi Jewish) | 4 | 0.8 | 1 | 0.5 | 3 | 1.1 | 0 | 0.0 | 1.00 |
| Colon | 70 | 14.0 | 5 | 2.7 | 60 | 21.1 | 5 | 15.6 | <0.0001 |
| Polyposisd | 59 | 11.8 | 12 | 6.5 | 47 | 16.6 | 0 | 0.0 | 0.0003 |
| Prostate | 8 | 1.6 | 1 | 0.5 | 4 | 1.4 | 3 | 9.4 | 0.01 |
| Melanoma | 21 | 4.2 | 6 | 3.3 | 10 | 3.5 | 5 | 15.6 | 0.02 |
| Thyroid | 5 | 1.0 | 2 | 1.1 | 2 | 0.7 | 1 | 3.1 | 0.31 |
a
Percent of total patients with risk assessment (500)
b
High risk cluster includes ≥3 cases of (in one lineage): bladder, brain, endometrial, esophageal, kidney, lung, mouth or throat, multiple myeloma, pancreatic, sarcoma, other skin cancer, testicular, hematological malignancies (in first or second degree relatives)
c
A category created for participants reporting genetic testing results and/or a known hereditary cancer syndrome which would place subject in high risk category regardless of family history
d
Polyposis defined as a moderate risk category (modification to existing criteria)